#1R 启明医疗 VENUSMEDTECH Ⓡ Investor Presentation Venus Medtech 2021 Annual Report#21 Disclaimer By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: 日 启明医疗® VENUSMEDTECH The information in this presentation has been prepared by representatives of Venus Medtech (Hangzhou) Inv. (the "Company" ) for use in presentation by the company at investor meetings for information purposes. No part of this presentation should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. Neither the Company nor any of its directors, supervisors, officers, partners, employees, affiliates, agents, advisors or representatives shall have any responsibility or liability whatsoever( for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially. This presentation is based on the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor any of its directors, supervisors, officers, partners, employees, affiliates, agents, advisors or representatives is under an obligation to update, revise or affirm. "I 11 The information communicated in this presentation contains certain statements that are or may be forwarding-looking. These statements typically contain words such as "will" "may" expert" "forecast" plan "and "anticipate "and words of similar import. By their nature forward-looking statement involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, readers should not rely on these forward-looking statements. The Company assumes no responsibility to update the forward-looking statements or to adapt them to future events or developments. This presentation and the information contained herein does not constitute or form part of any offer to sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company in any jurisdiction. This presentation and the information contained herein is highly confidential and being furnished to you solely for your information and may not be reproduced or redistributed in any manner to any other person, in whole or in part. In particular, neither the information contained in this presentation nor any copy hereof may be, directly or indirectly, taken or transmitted into or in the United States, Canada, Australia, Japan, Hong Kong or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of U.S. or other national securities laws. No money, securities or other consideration is being solicited, and, if sent in response to this presentation or the information contained herein, will be accepted. By attending this presentation, you acknowledge that you will be solely responsible for you own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company. Any decision to purchase securities in the context of a proposed offering of securities, if any, should be made solely on the basis of information contained in an offering circular or prospectus prepared in relation to such offering. By reviewing this presentation, you are deemed to have represented and agreed that you and any customers you represent are neither (i) a "qualified institutional buyer" (within the meaning of Rule 14A under the United States Securities Act of 1933, as amended), or (ii) outside the Unites States. Yor re also deemed to have represented and agreed that you and any customers you represent are professional investors as defined in the Securities and Futures Ordinance( Chapter 571 of the Laws of Hong Kong) and any rules made thereunder.#32 Content 01 Business Highlights 02 Commercial Review ||03 03 Global Innovation 2 启明医疗® VENUSMEDTECH#43 01 Business Highlights 2 启明医疗® VENUSMEDTECH#54 Business Highlights 21 Covering Structural Heart Diseases 3 Registration Application 5 Clinical Trials 日 启明医疗® VENUSMEDTECH VenusP-Valve, TriGUARD3, VenusA-Pro Cardiovalve, Liwen RF, Vitae, PowerX, Leaflex Leading the Chinese TAVR Market ✓ Full-year revenue RMB416 million, YOY up 50.6% ✓ 2021 procedure volume grew to 3600 ✓ Covering hospital 360, sales person 220 ✓ Overseas sales revenue RMB10.51 million YOY up 160.5% Continue to Lead the Market 22 Continue R&D and key product trials ➤ 4 Expected to enter into clinical trials: Cardiovalve(China), Liwen RF(Europe), Venus-Neo, RDN 3 Expected to be launched products: VenusP-Valve, TriGUARD3, VenusA-Pro ➤ Maintaining market share 60%~65% ➤ Hospital coverage 400 above ➤ Sales team 300 above#65 02 Commercial Performance R 启明医疗 VENUSMEDTECH#76 Financial Review R 启明医疗 VENUSMEDTECH Sales Revenue China Revenue Overseas Revenue 276.0 2020 50.6% Unit: million RMB 415.9 272.0 2020 2021 49.0% 405.3 Unit: million RMB 160.5% 10.5 4.0 2021 2020 Unit: million RMB 2021#87 Largest Share of Market in China R 启明医疗® VENUSMEDTECH 2021 Market Share ~70% 2021 procedure volume 3600 VenusA-Plus occupied 35% volume Hospital covered 360 Sales person reached 220 Cumulative procedure 9000+ *Data source 1. China National Center for Cardiovascular Diseases (20220114) 2. Chinese Journal of Interventional Cardiology, 2022,30 (1) 3. Company data A Top-tier hospitals volume grow steadily Mid-tier hospitals volume increase sharply#98 TAVR Training and Education 『大师』说 TAVR经验大师 2021年9月18日 『大师』范 TAVR经验大师 启明医疗 2021年8月18日 VENUSMEDTECH 谷兴华 教授 山东大学齐鲁医院 『大师』说 『大师』范 TAVR经验大师 2021年8月27日 本期嘉宾 任法新教授 『大师』说 帮助更多医者开启TAVR之旅 授业解惑 帮助更多医者开启TAVR之旅 【TAVR Master Series】 Master Show& Master Talk: Held over 10 activities including live broadcast, seminars R 启明医疗 VENUSMEDTECH ® 2021 TAVR最强音 第二届病例大赛总决赛颁奖典礼 【2021 Season 2 Venus X Factor】 Focus on difficult and complicated TAVR cases Work with national experts in structural heart Promote high-quality development of TAVR#109 Overseas sales grow steadily Joyce Heo was R 启明医疗 VENUSMEDTECH Shakeel Osman was appointed as SVP of sales in Europe, responsible for sales and marketing in congenital heart disease in Mar 2022 Europe David Brean was appointed as VP of sales in Europe, responsible for adult structural heart disease as well as the direct sales in Germany, France in 2021 2021 overseas revenue Sales 10.51 Latin America appointed as sales director responsible for new maker in Mar 2022 million RMB Southeast Asia Growth Rate 160.5% Overseas sales team expanded, Venus P-Valve was approved on April 8th in Europe#1110 03 Global Innovation 2 启明医疗® VENUSMEDTECH#1211 Heart Valve Product Pipeline Product Pre-clinical Aortic Valve VenusA-Valve Clinical R 启明医疗 VENUSMEDTECH Registration Launch Successfully registered in Columbia, Brazil, Philippines, Thailand, Kyrgyzstan Successfully registered in Thailand, Kyrgyzstan VenusA-Plus TAVR VenusA-Pro Registration under review Venus-Vitae FIM Venus-PowerX FIM AR valve R&D TAVr Leaflex Pi-Cardia FIM Venus-Neo FIM SAVR Small Incision Surgical Valve R&D VenusP-Valve Pulmonic Valve TPVR TMVR Cardiovalve Mitral valve VALGEN MEDTECH MitralStitch 德晋医疗 TMVr VALGEN MEDTECH DragonFly 德晋医疗 Tricuspid Valve TTVR Cardiovalve Accessories CEP TriGUARD3 Registration under review, Green Path CE Marking Clinical trial preparation Europe clinical trial, US: EFS preparation Registered trial Registered trial patients enrollment finished Clinical trial preparation EU: EFS US: EFS preparation Registration under review, Green Path CE Marking China status Global status Partner' s status#1312 Cardiovalve 3 启明医疗 VENUSMEDTECH In Jan 2022, Venus Medtech acquired Cardiovalve, a Israeli company and established the Venus Global Heart Valve Innovation Center in Israel to leverage Cardiovalve technology platform and develop a new generation of AR valve. Feature ➤ Fits both MR & TR Dual frame self-expanding Nitinol Valve design modeled on an established surgical mitral valve, aiming to provide a low ventricular profile, minimizing LVOTO risk, potentially providing more durability ➤ Through transfemoral access#1413 Global TMVR Products Comparison R 启明医疗 VENUSMEDTECH Cardiovalve CARDIOVALVE Cephea Abbott Intrepid Medtronic Tendyne Abbott Product Figure Delivery Size Clinical Studies Transfemoral 28F EU&U.S. EFS Transfemoral 32F FIM ww Transapical/ Transfemoral 35F EFS Anchoring Mitral valve leaflets/annulus Mitral valve leaflets/annulus Perimeter oversizing Transapical 34-36F CE Mark 2020 Apical pad#1514 Cardiovalve Initial Clinical Results 90% secondary MR pts, 80% pts with heart failure hospitalization in past year Age (years) Baseline Characteristics (N=11) R 启明医疗 VENUSMEDTECH 73±6.2 STS (Avg, Min, Max) 7 (2,16) Etiology Secondary MR 90% (10) NYHA III/IV 90% (10) Mixed 10% (1) Prior HF Hospitalization in past 80% (9) Severe MR 100% (11) year (%) Prior cardiovascular surgery (%) 45% (5) Atrial Fibrillation(%) 77.2% (8) The occurrence rate of LVOT obstruction in TMVR 9.3%*, Cardiovalve post- operation LVOT obstruction 0%; procedure completed 100% Procedure Parameters (N=11) LVOT Obstruction (%) 0% (0) Procedure Completed (Device Implanted) (%) 100% *Core Lab assessment Source: TMVR introduction and challenges (I), AP-SHD, 20190916#1615 R 启明医疗 VENUSMEDTECH Cardiovalve Initial Clinical Results Before:100% pts > Moderate MR After: immediate 100% pts≤Mild MR, 30 days 76% pts maintain≤Mild MR Precent Of patients 100 10% 90 27% 80 70 38% 60 60% 63% 50 40 30 20 38% 40% 12% 10 12% 0 Baseline Post Procedure 30 days Severe ■Mod-Sev Moderate Mild None#1716 Global Clinical Trial Progress Rapidly R 启明医疗 VENUSMEDTECH TR TRICUSPID valve MITRAL valve MR ➤ Completed successfully implantation in 13 patients (compassionate route in Canada, Italy and Germany) EFS in Europe ongoing EFS in US in preparation, approved as a breakthrough designated therapy ➤ Completed successfully a clinical study in 11 patients, the longest follow-up, of the first patient, is approaching 4 years ➤ AHEAD EU study commenced in 5 European Countries ➤ AHEAD US EFS study in preparation#1817 Venus-PowerX On December 2021, Venus-PowerX completed its First-in-Man clinical trial at West China Hospital of Sichuan University. 全释放 全回收 InVision Feature ➤ Self-expanding TAVR ➤ Active anti-paravalvular leak technology ➤ Dry tissue for storage and reduced glutaraldehyde ➤ Anti-calcification technology, long-term durability ➤ 100% retrieving R 启明医疗® VENUSMEDTECH#1918 Venus-Vitae On December 16, 2021 the Company successfully completed the first two implantations in the First-in-Man clinical trial at Instituto De Cardiologia Hospital in Argentina. Feature 日 启明医疗® VENUSMEDTECH vitae Balloon-expandable TAVR ➤Valve lock wire design ensures accurate positioning and deployment ➤ Supra-annular prosthesis design Dry tissue for durability, storage and calcification reduction#2019 VenusP-Valve R 启明医疗 VENUSMEDTECH Feature The only Chinese pulmonic valve product used in Europe and Americas the first self-expanding pulmonic valve product approved for marketing in Europe Included in the "Special Review Procedure for Innovative Medical Devices" by NMPA, registration application under review in China ➤ In Mar 2021, Special Use granted by the U.K. MHRA and sales in some designated hospitals in U.K. On April 8th, obtained CE Marking under MDR#21VenusP-Valve 2 Year Follow-up Results Clinical trial results show "0" occurrence of dearth or reoperation R 启明医疗 VENUSMEDTECH 20 20 Procedural success 79(100%) Mortality rate at 6-month 0% Mortality rate at 12-month 0% Mortality rate at 2-year 0% Procedural success 79(100%) Re-operation rate at 6-month 0% Re-operation rate at 12-month 0% Re-operation rate at 2-year 0%#22VenusP-Valve 2 Year Follow-up Results 日 启明医疗® VENUSMEDTECH Before:100%≥ Moderate PR, After: 1 Year 100% ≤ Mild PR, 2 Year 98.56% ≤Mild PR Pulmonic Regurgitation (PR) 100% 90% 3.80% 1.37% 6.85% 1.54% 13.04% 20.00% 80% 70% 60% 83.12% 36.71% 49.32% 39.13% 46.15% 50% 40% 30% 20% 59.49% 47.83% 42.47% 32.31% 10% 16.88% 0% baseline 1M 6M 1Y 2Y Severe PR 83.12% 0.00% 0.00% 0.00% 1.54% Moderate PR 16.88% 0.00% 1.37% 0.00% 0.00% Mild PR 0.00% 3.80% 6.85% 13.04% 20.00% Trivial PR 0.00% 36.71% 49.32% 39.13% 46.15% NO PR 0.00% 59.49% 42.47% 47.83% 32.31% 21#23Liwen RF Ablation System 屈 启明医疗® VENUSMEDTECH In Sep 2021, Venus Medtech entered into share transfer agreement to acquire the shares of Hangzhou Nuocheng Medical Technology Co.,Ltd to obtain its Liwen RF ablation system for treatment of hypertrophic cardiomyopathy. Feature Global novel HCM treatment: echocardiography- guided percutaneous intramyocardial septal radiofrequency ablation Compared with surgical myectomy and alcohol septal ablation, less invasive, short recovery, less damage to conduction system, lower recurrence rate and mortality rate Controlled ablation power and range, complete ablation 22 22#2423 Multi-center Clinical Trial ongoing Leading Teams Professor Junbo Ge, Professor Yun Zhang lead the clinical study Principal ✓ Investigator Professor Liwen Liu, the inventor of Liwen is the PI of the study Medical Centers Efficacy 28 centers planned, 21 centers active, including Xijing Hospital, Zhongshan Hospital at Fudan University etc. Clinical trial ongoing, 11 patients finished 1 month follow-up, success rate 100% R 启明医疗 VENUSMEDTECH UMED MEDICAL Ο#2524 24 RDN Ultrasound Ablation B 启明医疗® VENUSMEDTECH In June 2021, Venus Medtech formed a joint venture company with Healium, an Israeli high technology company, to introduce and R&D, manufacture and commercialize RDN innovative system worldwide. healium Medical Ultrasound Ablation Catheter 6FR Side Facing Ablation Platform Procedure Analysis Dashboard Current ange 360 Power: 0 (w) Energy: 424 Distance: 11.7 (mm) A angle: 30 (deg) Ablation Time: 0 (s) TAT: 00:03:54h Echomplish Procedure Software Echomplish Ultrasound Console O#2625 25 RDN Ultrasound Ablation R 启明医疗 VENUSMEDTECH Non-contact ablation can be used in the treatment of pulmonary hypertension Continuous Rotation Time=0 s Surface: Temperature (deg C) Contour: Temperature (degC) mm 20 15 10 5 0 -5 -10 -15- -20 60 37.0 55 O 50 -20 -10 0 10 20 mm Step by Step Rotation Time=0 s Surface: Temperature (degC) Contour: Temperature (degC) mm 22- 20- 18 16- 14- 12 10 8 6 4 45 2 0 -2 40 -4 I -15 -10 -5 0 5 10 15 mm 60 55 50 45 40#2726 Global Intellectual Properties Portfolio Ranking the 1st in numbers Until Feb 28 2022, there are 756 patent application and 315 issued patens In-depth layout Detailed IP portfolio in key technology such as latest dry-tissue, balloon expandable valve, anti-paravalvular leak technology. U.S. R&D Center IP Covered R 启明医疗 VENUSMEDTECH Wide coverage IP covers China, U.S., Europe, Japan, Canada, Russia, India, Brazil 75% invention patents Hangzhou R&D Center Israel R&D Center Risk Control Comprehensive risk control of the entire life cycle of products#28Thanks! 鳳 启明医疗 VENUSMEDTECH